Maa: Kanada
Kieli: englanti
Lähde: Health Canada
CIMETIDINE
MEDTECH PRODUCTS INC
A02BA01
CIMETIDINE
200MG
TABLET
CIMETIDINE 200MG
ORAL
100
OTC
HISTAMINE H2-ANTAGONISTS
Active ingredient group (AIG) number: 0111925005; AHFS:
APPROVED
2023-04-06
_ _ _Page 1 of 24_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION TAGAMET® PREVENT Cimetidine Tablets Tablet, 200 mg, Oral USP Histamine H 2 – Receptor Antagonist ATC Code: A02BA01 Medtech Products Inc. 660 White Plains Rd., Suite 250 Tarrytown, NY 10591 USA Date of Initial Authorization: Apr 12, 2000 Date of Revision: Mar 22, 2023 Submission Control Number: 270508 _ _ _ _ _Page 2 of 24_ RECENT MAJOR LABEL CHANGES None. TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED . RECENT MAJOR LABEL CHANGES ............................................................................................ 2 TABLE OF CONTENTS .............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ...................................................................... 4 1 INDICATIONS ............................................................................................................... 4 1.1 Pediatrics ................................................................................................................ 4 1.2 Geriatrics ................................................................................................................ 4 2 CONTRAINDICATIONS ................................................................................................. 4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ............................................................ 4 4 DOSAGE AND ADMINISTRATION ................................................................................. 4 4.1 Dosing Considerations ............................................................................................ 4 4.2 Recommended Dose and Dosage Adjustment ....................................................... 5 4.5 Missed Dose ........................................................................................................... 5 5 OVERDOSAGE ................................................ Lue koko asiakirja